Mechanisms controlling the effects of bevacizumab (Avastin) on the inhibition of early but not late formed corneal neovascularization

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Chen, Wei Li ^a   Chen, Yan Ming ^a,b   Chu, Hsiao Sang ^a   Lin, Chung Tien ^c   Chow, Lu Ping ^d   Chen, Chih Ta ^d   Hu, Fung Rong ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AM 3K; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ACTIN; ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; HMW-MAA; TUMOR ANTIGEN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA NEOVASCULARIZATION; CORNEA STROMA; DISEASE SEVERITY; DRUG DIFFUSION; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MACROPHAGE MIGRATION; NONHUMAN; PERICYTE; PROTEIN EXPRESSION; RABBIT; SMOOTH MUSCLE FIBER; TIME TO TREATMENT; TREATMENT DURATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CORNEA; CORNEAL NEOVASCULARIZATION; DRUG EFFECTS; METABOLISM; PATHOLOGY;

ACTINS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD31; ANTIGENS, NEOPLASM; CORNEA; CORNEAL NEOVASCULARIZATION; IMMUNOHISTOCHEMISTRY; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84899571771     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094205     Document Type: Article

References (77)

1. Cogan DG (1962) Corneal neovascularization. Invest Ophthalmol Vis Sci 1: 253-261.
2. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP (1998) Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39: 18-22. (Pubitemid 28040457)
3. Cursiefen C, Kuchle M, Naumann GO (1998) Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 17: 611-613. (Pubitemid 28511907)
4. Lee P, Wang CC, Adamis AP (1998) Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 43: 245-269. (Pubitemid 28558273)
5. Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12: 242-249. (Pubitemid 32751680)
6. Cursiefen C, Cao J, Chen L, Liu Y, Maruyama K, et al. (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45: 2666-2673. (Pubitemid 38998863)
7. Dastjerdi MH, Saban DR, Okanobo A, Nallasamy N, Sadrai Z, et al. (2010) Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci 51: 2411-2417.
8. Bachmann B, Taylor RS, Cursiefen C (2010) Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 117: 1300-1305.
9. Dana MR, Schaumberg DA, Kowal VO, Goren MB, Rapuano CJ, et al. (1995) Corneal neovascularization after penetrating keratoplasty. Cornea 14: 604-609.
10. Benelli U, Ross JR, Nardi M, Klintworth GK (1997) Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A. Invest Ophthalmol Vis Sci 38: 274-282. (Pubitemid 27085683)
11. Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41: 2514-2522. (Pubitemid 30624378)
12. Zakaria N, Van Grasdorff S, Wouters K, Rozema J, Koppen C, et al. (2012) Human tears reveal insights into corneal neovascularization. PLoS One 7: e36451.
13. Cursiefen C, Ikeda S, Nishina PM, Smith RS, Ikeda A, et al. (2005) Spontaneous corneal hemangiogenesis and lymphangiogenesis in mice with destrinmutation depend on VEGFR3 signaling. Am J Pathol 166: 1367-1377. (Pubitemid 40586508)
14. Azar DT (2006) Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 104: 264-302.
15. Miller JW, Adamis AP, Aiello LP (1997) Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 13: 37-50. (Pubitemid 27213792)
16. Aiello LP (1997) Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 29: 354-362.
17. Mastyugin V, Mosaed S, Bonazzi A, Dunn MW, Schwartzman ML (2001) Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res 23: 1-10. (Pubitemid 34494008)
18. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991.
19. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, et al. (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579-1586.
20. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Møller NP, et al. (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846. (Pubitemid 23110226)
21. Quinn TP, Peters KG, De VC, Ferrara N, Williams LT (1993) Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90: 7533-7537. (Pubitemid 23249984)
22. Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, et al. (2008) Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 145: 424-431.
23. Chen WL, Lin CT, Lin NT, Tu IH, Li JW, et al. (2009) Subconjunctival injection of bevacizumab (Avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 50: 1659-1665.
24. Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, et al. (2008) Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 27: 357-362. (Pubitemid 351440874)
25. Kim TI, Kim SW, Kim S, Kim T, Kim EK (2008) Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 27: 349-352. (Pubitemid 351440872)
26. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, et al. (2007) Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 35: 745-748. (Pubitemid 350090533)
27. Lin CT, Hu FR, Kuo KT, Chen YM, Chu HS, et al. (2010) Early but not late treatment with bevacizumab (Avastin) can inhibit corneal neovascularization and conjunctivalization in rabbit limbal insufficiency. Invest Ophthalmol Vis Sci 51: 6277-6285.
28. Chen WL, Chen YM, Chu HS, Lin YH, Tsai TY, et al. (2009) Bevacizumab for the Treatment of Corneal Neovascularization. Cornea 28: S26-S30.
29. Chu HS, Hu FR, Yang CM, Yeh PT, Chen YM, et al. (2011) Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovascularization Associated with Lipid Deposition. Cornea 30: 60-66.
30. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, et al. (2008) Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 49: 522-527.
31. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342. (Pubitemid 38702844)
32. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, et al. (2006) Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113: 1695.e1-15.
33. Nicholson BP, Schachat AP (2010) A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 248: 915-930.
34. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, et al. (2010) A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema. (BOLT study) 12-month data: report 2. Ophthalmology 117: 1078-1086.
35. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, et al. (2005) Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89: 1368-1370. (Pubitemid 41638883)
36. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112: 1035-1047. (Pubitemid 40797459)
37. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363-372 e365.
38. Moreno SF, Paloma JB (2008) Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy. Br J Ophthalmol 92: 866-867.
39. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, et al. (2007) Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91: 804-807. (Pubitemid 46846656)
40. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI (2008) The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115: e33-38.
41. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A (2008) Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33: 23-28. (Pubitemid 351156952)
42. Qian J, Lu Q, Tao Y, Jiang YR (2011) Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina 31: 161-168.
43. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nör JE (2010) VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ 17: 499-512.
44. Kubota T, Morita H, Tou N, Nitta N, Tawara A, et al. (2010) Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab. Retina 30: 468-472.
45. Cursiefen C, Hofmann-Rummelt C, Kuchle M, Schlotzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation. Br J Ophthalmol 87: 101-106. (Pubitemid 36071788)
46. Motiejūnaite R, Kazlauskas A (2008) Pericytes and ocular diseases. Exp Eye Res 86: 171-177.
47. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, et al. (2003) Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am J Pathol 162: 183-193. (Pubitemid 36042000)
48. Bandopadhyay R, Orte C, Lawrenson JG, Reid AR, de Silva S, et al. (2001) Contractile proteins in pericytes at the blood-brain and blood-retinal barriers. J Neurocytol 30: 35-44.
49. Skalli O, Pelte MF, Peclet MC, Gabbiani G, Gugliotta P, et al. (1989) α-Smooth muscle actin, a different marker of smooth muscle cells, is present in microfilamentous bundles of pericytes. J Histochem Cytochem 37: 315-321. (Pubitemid 19063429)
50. Dhar K, Dhar G, Majumder M, Haque I, Mehta S, et al. (2010) Tumor cell-derived PDGF-B potentiates mouse mesenchymal stem cells-pericytes transition and recruitment through an interaction with NRP-1. Mol Cancer 9: 209.
51. Nisancioglu MH, Betsholtz C, Genove G (2010) The absence of pericytes does not increase the sensitivity of tumor vasculature to vascular endothelial growth factor-A blockade. Cancer Res 70: 5109-5115.
52. Schlingemann RO, Rietveld FJ, de Waal RM, Ferrone S, Ruiter DJ (1990) Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 136: 1393-1405. (Pubitemid 20210338)
53. Komohara Y, Hirahara J, Horikawa T, Kawamura K, Kiyota E, et al. (2006) AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 54: 763-771. (Pubitemid 43946243)
54. Zeng L, Takeya M, Takahashi K (1996) AM-3K, a novel monoclonal antibody specific for tissue macrophages and its application to pathological investigation. J Pathol 178: 207-214.
55. Fujita S, Saika S, Kao WW, Fujita K, Miyamoto T, et al. (2007) Endogenous TNFalpha suppression of neovascularization in corneal stroma in mice. Invest Ophthalmol Vis Sci 48: 3051-3055. (Pubitemid 351261147)
56. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, et al. (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48: 2545-2552. (Pubitemid 351261204)
57. Fujita N, Fujita S, Okada Y, Fujita K, Kitano A, et al. (2010) Impaired angiogenic response in the corneas of mice lacking osteopontin. Invest Ophthalmol Vis Sci 51: 790-794.
58. Kohno R, Hata Y, Mochizuki Y, Arita R, Kawahara S, et al. (2010) Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection. Am J Ophthalmol 150: 223-229.
59. Dell S, Peters S, Müther P, Kociok N, Joussen AM (2006) The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest Ophthalmol Vis Sci 47: 1928-1937. (Pubitemid 46768273)
60. McCracken JS, Burger PC, Klintworth GK (1979) Morphologic observations on experimental corneal vascularization in the rat. Lab Invest 41: 519-530. (Pubitemid 10168519)
61. Ashton N, Oliveira F (1966) Nomenclature of pericytes: intramural and extramural. Br J Ophthalmol 50: 119-123.
62. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, et al. (1996) A model of angiogenesis in the mouse cornea. Invest. Ophthalmol Vis Sci 37: 1625-1632. (Pubitemid 26271414)
63. Alon T, Hemo I, Itin A, Pe'er J, Stone J, et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024-1028.
64. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165. (Pubitemid 29053133)
65. Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125: 1591-1598. (Pubitemid 28256727)
66. Darland DC, D'Amore PA (1999) Blood vessel maturation: vascular development comes of age. J Clin Invest 103: 157-158. (Pubitemid 29053132)
67. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG (1998) Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 78: 1385-1394. (Pubitemid 28546082)
68. Moore JW 3rd, Sholley MM (1985) Comparison of the neovascular efects of stimulated macrophages and neutrophils in autologous rabbit corneas. Am J Pathol 120: 87-98.
69. Li ZR, Li YP, Lin ML, Su WR, Zhang WX, et al. (2012) Activated macrophages induce neovascularization through upregulation of MMP-9 and VEGF in rat corneas. Cornea 31: 1028-1035.
70. Nucera S, Biziato D, De Palma M (2011) The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. Int J Dev Biol 55: 495-503.
71. Anghelina M, Krishnan P, Moldovan L, Moldovan NI (2006) Monocytes/macrophages cooperate with progenitor cells during neovascularization and tissue repair: conversion of cell columns into fibrovascular bundles. Am J Pathol 168: 529-541. (Pubitemid 43271151)
72. Urao N, Razvi M, Oshikawa J, McKinney RD, Chavda R, et al. (2010) IQGAP1 is involved in post-ischemic neovascularization by regulating angiogenesis and macrophage infiltration. PLoS One 5: e13440.
73. Salnikov AV, Heldin NE, Stuhr LB, Wiig H, Gerber H, et al. (2006) Inhibition of carcinoma cell-derived VEGF reduces inflammatory characteristics in xenograft carcinoma. Int J Cancer 119: 2795-2802. (Pubitemid 44846230)
74. Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, et al. (2009) Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 4: e7669.
75. Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, et al. (2008) Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 68: 4340-4346.
76. Safvati A, Cole N, Hume E, Willcox M (2009) Mediators of neovascularization and the hypoxic cornea. Curr Eye Res 34: 501-514.
77. Pérez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, Javaloy J, Alió JL (2010) Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model. Am J Ophthalmol 150: 519-528.